# Air Pollution (PM2.5) on Accelerated Atherosclerosis: A Montelukast Interventional Study in Modernizing China

Study · id `cardio:ct-nct04762472` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04762472](<https://clinicaltrials.gov/study/NCT04762472>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04762472

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT04762472. Randomized; triple masking; primary purpose prevention. Start 2023-09 (anticipated); primary completion 2024-12-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT04762472, source copy `cardio:ctgov-nct04762472-2023-02-13`, retrieved 2026-10-26)
- Planned start: 2023-09 (anticipated) (ClinicalTrials.gov record NCT04762472, source copy `cardio:ctgov-nct04762472-2023-02-13`, retrieved 2026-10-26)
- Primary completion: 2024-12-30 (anticipated) (ClinicalTrials.gov record NCT04762472, source copy `cardio:ctgov-nct04762472-2023-02-13`, retrieved 2026-10-26)
- Completion: 2025-12-30 (anticipated) (ClinicalTrials.gov record NCT04762472, source copy `cardio:ctgov-nct04762472-2023-02-13`, retrieved 2026-10-26)
- Countries: Hong Kong SAR China (ClinicalTrials.gov record NCT04762472, source copy `cardio:ctgov-nct04762472-2023-02-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04762472-2023-02-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Air Pollution (PM2.5) on Accelerated Atherosclerosis: A Montelukast Interventional Study in Modernizing China
- Condition: Atherosclerosis, Coronary
- Intervention (Drug): Montelukast Oral Tablet
- Intervention (Drug): Montelukast Placebo Oral Tablet
- Lead sponsor: Chinese University of Hong Kong
- Lead sponsor class: OTHER
- Collaborator: People's Hospital of Chongqing
- Collaborator class: OTHER
- Collaborator: Hong Kong University of Science and Technology
- Collaborator class: OTHER
- Collaborator: Chongqing Medical University
- Collaborator class: OTHER
- Collaborator: University of Sydney
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Chinese University of Hong Kong (`cardio:org-chinese-university-of-hong-kong`)
- Registry lists this organization as a collaborator: Chongqing Medical University (`cardio:org-chongqing-medical-university`)
- Registry lists this organization as a collaborator: University of Sydney (`cardio:org-university-of-sydney`)

## Provenance

Content hash: 8af94737bdb0205e42c3c60ceaa815018f62113235cc784d3683a011399e53cd
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
